RUNX1 is a member of the core-binding factor family of transcription factors and is
indispensable for the establishment of definitive hematopoiesis in vertebrates. RUNX1 is …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications
(ITDs) have poor outcomes, in particular AML with a high (≥ 0.5) mutant/wild-type allelic …

Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid
leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic …

Background Mutations occur in several genes in cytogenetically normal acute myeloid
leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 …

Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic
progenitor cells and the most common malignant myeloid disorder in adults. The median …

Abstract Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia
(AML) do not achieve complete remission with intensive induction therapy and are therefore …

Purpose To evaluate the prognostic significance of the international European LeukemiaNet
(ELN) guidelines for reporting genetic alterations in acute myeloid leukemia (AML). Patients …

The clinical value of serial minimal residual disease (MRD) monitoring in core binding factor
(CBF) acute myeloid leukemia (AML) by quantitative RT-PCR was prospectively assessed in …

Acute myeloid leukemia (AML) with t (8; 21) or inv (16) have been recognized as unique
entities within AML and are usually reported together as core binding factor AML (CBF …